NASDAQ · DMAC

DiaMedica Therapeutics Inc.

$6.74 +$0.00 (+0.07%) 1D After hours

Key Metrics

$362.90M
Market cap
P/E · TTM
Revenue · TTM
−$35.10M
Net income
EPS · TTM $-0.82
Dividend yield
Free cash flow −$31.03M
Beta · 1Y 1.76
EBITDA · TTM −$35.03M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 29
    The stock moved +10.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 29
  • Jun 10
    From its Feb 17 high, the share price fell 39%.

    Peak close $8.70 on Feb 17; trough close $5.33 on Jun 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -39%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$362.90M
Enterprise value
Shares outstanding53.9M
52-wk range$4.01 – $10.42
Avg volume · 20D147.6K
Net cash
Book value / share$1.10
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About DiaMedica Therapeutics Inc.
IPO dateNov 29, 2007
Employees35

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE).

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -79.8% · 857.0%

Financial Health

Current ratio9.11
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$46.62M

Cash Flow · TTM

Operating CF −$31.00M
Capex −$36.00K
Free cash flow −$31.03M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings